4 Analysts Have This to Say About Coherus BioSciences
Portfolio Pulse from Benzinga Insights
Four analysts have given bullish ratings for Coherus BioSciences (NASDAQ:CHRS) in the last quarter, with an average price target of $18.0, implying an upside from the current price of $4.05. This average has decreased by 21.74% from the previous average price target of $23.00.
September 26, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bullish ratings from four analysts suggest a potential upside for Coherus BioSciences, despite a decrease in the average price target.
The bullish ratings from four analysts indicate a positive outlook for Coherus BioSciences. However, the decrease in the average price target suggests that the expected upside may be lower than previously anticipated.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100